Validation of a liquid chromatographic method for the determination of ibuprofen in human plasma

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 780, Issue 2, 2002, Pages 341-348

  Farrar, Henry ^a   Letzig, Lynda ^a   Gill, Michael ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b BASF Corporation   (United States)

Author keywords

Ibuprofen

Indexed keywords

CALIBRATION; EXTRACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SAMPLING; ULTRAVIOLET DETECTORS;

HUMAN PLASMA;

CHROMATOGRAPHIC ANALYSIS;

IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ACCURACY; ARTICLE; BIOEQUIVALENCE; BLOOD ANALYSIS; BLOOD SAMPLING; CALIBRATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; FOOD; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PRIORITY JOURNAL; ROOM TEMPERATURE; SAMPLING; SOLID PHASE EXTRACTION; STANDARD; TIME; VALIDATION PROCESS; BLOOD; METHODOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; ULTRAVIOLET SPECTROPHOTOMETRY; VALIDATION STUDY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; IBUPROFEN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 0037175437     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1570-0232(02)00543-3     Document Type: Article

References (11)

1. Insel P. Hardman J.G., Limbird L.E., Goodman and Gilman's the Pharmacologic Basis of Therapeutics. 9th ed. 1996;617 McGraw-Hill, New York.
2. Linder W., Wainer I.W. J. Chromatogr. B. 707:1998;1.
3. Guidance for Industry: Bioanalytical Method Validation, Center for Drug Evaluation and Research, United States Food and Drug Administration.
4. Guidance: Naproxen tablets in vivo bioequivalence and in vitro dissolution. Division of Bioequivalence of the Center for Drug Evaluation and Research, United States Food and Drug Administration.
5. Guidance: Statistical procedures for bioequivalence studies using a standard two treatment crossover design. Division of Bioequivalence of the Center for Drug Evaluation and Research, United States Food and Drug Administration.
6. Avgerinos A., Hutt A.J. J. Chromatogr. 380:1986;468.
7. Rustum A. J. Chromatogr. Sci. 29:1991;16.
8. Wright M.R., Sattari S., Brocks D.R., Jamali F. J. Chromatogr. 583:1992;259.
9. Lemko C.H., Caille G., Foster R.T. J. Chromatogr. 619:1993;330.
10. Gasco-Lopez A.I., Izquierdo-Hornillos R., Jiminez A. J. Pharm. Biomed. Anal. 21:1999;143.
11. Bhushan R., Martens J. Biomed. Chromatogr. 12:1998;309.